| Literature DB >> 25215242 |
Robert W Jordan1, Gurdip S Chahal1, Anna Chapman2.
Abstract
Introduction. End-stage ankle osteoarthritis is a debilitating condition. Traditionally, ankle arthrodesis (AA) has been the surgical intervention of choice but the emergence of total ankle replacement (TAR) has challenged this concept. This systematic review aims to address whether TAR or AA is optimal in terms of functional outcomes. Methods. We conducted a systematic review according to PRISMA checklist using the online databases Medline and EMBASE after January 1, 2005. Participants must be skeletally mature and suffering from ankle arthrosis of any cause. The intervention had to be an uncemented TAR comprising two or three modular components. The comparative group could include any type of ankle arthrodesis, either open or arthroscopic, using any implant for fixation. The study must have reported at least one functional outcome measure. Results. Of the four studies included, two reported some significant improvement in functional outcome in favour of TAR. The complication rate was higher in the TAR group. However, the quality of studies reviewed was poor and the methodological weaknesses limited any definitive conclusions being drawn. Conclusion. The available literature is insufficient to conclude which treatment is superior. Further research is indicated and should be in the form of an adequately powered randomised controlled trial.Entities:
Year: 2014 PMID: 25215242 PMCID: PMC4158286 DOI: 10.1155/2014/986285
Source DB: PubMed Journal: Adv Orthop ISSN: 2090-3464
Search strategy for Medline.
| Number | Search term | Results |
|---|---|---|
| 1 | exp Ankle Joint/or exp Ankle/ | 16259 |
| 2 | exp Arthroplasty, Replacement/or exp Arthroplasty/or exp Arthroplasty, Replacement, Ankle/ | 37169 |
| 3 | exp Arthrodesis/ | 22930 |
| 4 | 1 and 2 and 3 | 141 |
| 5 | limit 4 to (english language and humans) | 128 |
| 6 | limit 5 to yr = “2005–Current” | 88 |
Figure 1Flow diagram of review process.
Summary of the included studies.
| Study | Study Design | Population | Intervention | Comparator | Outcome measures (primary in bold) | Follow-up period | Significant results |
|---|---|---|---|---|---|---|---|
| Schuh et al., 2012 [ | Retrospective comparative study—level III | Adults with ankle osteoarthritis who have failed conservative treatment | HINTEGRA prosthesis—uncemented 3-component TAR | Arthrodesis with 3 ∗ cannulated screws | Patient satisfaction | 34.5 months | No significant results |
|
| |||||||
| Esparragoza et al., 2011 [ | Prospective comparative study—level II | Adult primary or secondary ankle arthritis | Ankle Evolution System prosthesis—uncemented 3-component TAR ( | Open arthrodesis with bone graft and either external fixator, screw fixation, or retrograde calcaneal nail ( | AOFAS | 24 months | Improved results in TAR group: |
|
| |||||||
| Krause et al., 2011 [ | Retrospective comparative study—level III | Adults with primary or secondary arthritis, revision of TAR to AA included | TAR with one of four uncemented prostheses: | Open or arthroscopic arthrodesis | AOS | Mean 37 months | Higher complication rate with TAR 54% versus 26% ( |
|
| |||||||
| Saltzman et al., 2010 [ | Retrospective comparative study—level III | Adult posttraumatic or primary ankle osteoarthritis | STAR prosthesis—uncemented 3-component TAR | Open arthrodesis with external fixator, plate fixation, or screw fixation ( | AOS | 4.2 years | Improved results in TAR group: |
Assessment of papers according to STROBE statement [24].
| Item number | Recommendation | Schuh et al., 2012 [ | Esparragoza et al., 2011 [ | Saltzman et al., 2010 [ | Krause et al., 2011 [ | |
|---|---|---|---|---|---|---|
| Title and abstract | 1 | (a) Indicate the study's design with a commonly used term in the title or the abstract. | No | Yes | No | No |
| (b) Provide in the abstract an informative and balanced summary of what was done and what was found. | Yes | Yes | Yes | Yes | ||
|
| ||||||
| Introduction | ||||||
| Background/rationale | 2 | Explain the scientific background and rationale for the investigation being reported. | Yes | Yes | Yes | Yes |
| Objectives | 3 | State specific objectives, including any prespecified hypotheses. | Yes | Yes | Yes | Yes |
|
| ||||||
| Methods | ||||||
| Study design | 4 | Present key elements of study design early in the paper. | No | Yes | Yes | Yes |
| Setting | 5 | Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection. | Yes | Yes | Yes | Yes |
| Participants | 6 | (a) | No | No | No | Yes |
| (b) | n/a | n/a | n/a | n/a | ||
| Variables | 7 | Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable. | Yes | Yes | Yes | Yes |
| Data | 8 | For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group. | No | No | No | Yes |
| Bias | 9 | Describe any efforts to address potential sources of bias. | No | No | No | Yes |
| Study size | 10 | Explain how the study size was arrived at. | No | No | No | No |
| Quantitative variables | 11 | Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why. | Yes | No | Yes | Yes |
|
|
| (a) Describe all statistical methods, including those used to control for confounding. | Yes | Yes | Yes | Yes |
| (b) Describe any methods used to examine subgroups and interactions. | n/a | n/a | n/a | n/a | ||
| (c) Explain how missing data were addressed. | No | n/a | No | No | ||
| (d) | No | n/a | No | n/a | ||
| (e) Describe any sensitivity analyses. | n/a | n/a | n/a | n/a | ||
| 13 | (a) Report numbers of individuals at each stage of study—for example, numbers of potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed. | No | No | Yes | Yes | |
| (b) Give reasons for nonparticipation at each stage. | No | n/a | Yes | Yes | ||
| (c) Consider use of a flow diagram. | No | No | No | No | ||
| Descriptive data | 14 | (a) Give characteristics of study participants (e.g., demographic, clinical, and social) and information on exposures and potential confounders. | No | Yes | Yes | Yes |
| (b) Indicate number of participants with missing data for each variable of interest. | No | No | No | No | ||
| (c) | Yes | Yes | Yes | |||
| Outcome data | 15 |
| No | No | No | No |
|
| ||||||
|
| ||||||
| Main results | 16 | (a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (e.g., 95% confidence interval). Make clear which confounders were adjusted for and why they were included. | No | No | No | No |
| (b) Report category boundaries when continuous variables were categorized. | n/a | n/a | n/a | n/a | ||
| (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period. | n/a | n/a | n/a | n/a | ||
| Other analyses | 17 | Report other analyses done—for example, analyses of subgroups and interactions and sensitivity analyses. | n/a | n/a | n/a | n/a |
|
| ||||||
| Discussion | ||||||
| Key results | 18 | Summarise key results with reference to study objectives. | Yes | Yes | Yes | Yes |
| Limitations | 19 | Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias. | Yes | No | Yes | Yes |
| Interpretation | 20 | Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant lines of evidence. | Yes | No | Yes | Yes |
| Generalisability | 21 | Discuss the generalisability (external validity) of the study results. | No | No | No | No |
|
| ||||||
| Other information | ||||||
| Funding | 22 | Give the source of funding and the role of the funders in the present study and, if applicable, in the original study on which the present paper is based. | No | No | No | Yes |
Reason for exclusion of studies after full paper review.
| Study | Reason for exclusion |
|---|---|
|
[ | Expert opinion |
| Conley et al., 2012 [ | No functional outcome recorded |
| Flavin et al., 2013 [ | No functional outcome recorded |
| Hahn et al., 2012 [ | No functional outcome recorded |
|
Krause and Schmid 2012 [ | No functional outcome recorded |
| Piriou et al., 2008 [ | No functional outcome recorded |
|
Rouhani et at., 2011 [ | Study participants divided into more than two groups |
|
Rouhani et al., 2012 [ | Study participants divided into more than two groups |
| Slobogean et al., 2010 [ | No functional outcome recorded |
| SooHoo et al., 2007 [ | No functional outcome recorded |